81 FR 164 pgs. 57925-57926 - Government-Owned Inventions; Availability for Licensing
Type: NOTICEVolume: 81Number: 164Pages: 57925 - 57926
Pages: 57925, 57926FR document: [FR Doc. 2016-20160 Filed 8-23-16; 8:45 am]
Agency: Health and Human Services Department
Sub Agency: National Institutes of Health
Official PDF Version: PDF Version
[top]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY:
National Institutes of Health, HHS.
ACTION:
Notice.
SUMMARY:
The invention listed below is owned by an agency of the U.S. Government and is available for licensing and/or co-development in the U.S. in accordance with 35 U.S.C. 209 and 37 CFR part 404 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing and/or co-development.
ADDRESSES:
Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702.
FOR FURTHER INFORMATION CONTACT:
Information on licensing and co-development research collaborations, and copies of the U.S. patent applications listed below may be obtained by contacting: Attn. Invention Development and Marketing Unit, Technology Transfer Center, National Cancer Institute, 9609 Medical Center Drive, Mail Stop 9702, Rockville, MD 20850-9702, Tel. 240-276-5515 or email ncitechtransfer@mail.nih.gov. A signed Confidential Disclosure Agreement may be required to receive copies of the patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Title of invention: Processes for Producing and Purifying Nucleic Acid-Containing Compositions.
[top] Description of Technology: This technology consists of improved processes for producing and purifying nucleic acid-containing compositions, such as non-naturally occurring viruses, for example, recombinant polioviruses that can be used as oncolytic agents. Some of the improved processes relate
Potential Commercial Applications:
• Large-scale manufacturing for producing highly purified, live virus.
• Improved viral purification process that:
? Increases the yield and/or purity of the resulting product, while decreasing the purification time;
? is generally applicable to purification of any nucleic acid molecule-containing composition, such as virus-based composition, and can be used for the purification of live native or recombinant viruses necessary for clinical applications.
• Improved process for generating viral template plasmid (such as one that includes a DNA template for an RNA virus), which addresses the problem of genetic instability of the plasmids containing the viral genome ( e.g., of a recombinant polio virus) in host ( e.g., bacterial) cells, in which the plasmids are typically propagated.
Value Proposition:
• Cost- and time-effective means of producing highly purified virus-based GMP products, such as oncolytic viruses, for regulatory approval.
Development Stage: Clinical Phase I.
Inventor(s): Trevor Broadt (NCI), Samir Shaban (NCI), Yueqing Xie (NCI), Jianwei Zhu (NCI), George Mitra (NCI).
Intellectual Property: HHS Ref. No. E-267-2014/0-US-01, corresponding to US Provisional Patent App. No. 62/173,777, filed June 10, 2015, entitled "Processes for Production and Purification of Nucleic Acid Containing Compositions.".
HHS Ref. No. E-267-2014/0-PCT-02, corresponding to International Patent App. No. PCT/US2016/036888, filed June 10, 2016, entitled "Processes for Production and Purification of Nucleic Acid Containing Compositions".
Publications: Ouellette et al., BioProcessing J. 2005 4(2):31-38.
Related Technologies: HHS Reference #E-240-2015/0 entitled "Methods of Analyzing Virus-Derived Therapeutics".
Contact Information: Requests for copies of the patent application or inquiries about licensing, research collaborations, and co-development opportunities should be sent to John D. Hewes, Ph.D., email: john.hewes@nih.gov.
Dated: August 16, 2016.
John D. Hewes,
Technology Transfer Specialist, Technology Transfer Center, National Cancer Institute.
[FR Doc. 2016-20160 Filed 8-23-16; 8:45 am]
BILLING CODE 4140-01-P